Plerixafor Patent Expiration
Plerixafor is Used for mobilizing hematopoietic stem cells in patients with non-Hodgkin's lymphoma and multiple myeloma for autologous transplantation. It was first introduced by Genzyme Corp
Plerixafor Patents
Given below is the list of patents protecting Plerixafor, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Mozobil | US6987102 | Methods to mobilize progenitor/stem cells |
Jul 22, 2023
(Expired) | Genzyme |
| Mozobil | US7897590 | Methods to mobilize progenitor/stem cells |
Jul 22, 2023
(Expired) | Genzyme |
| Mozobil | USRE42152 | Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity |
Dec 10, 2018
(Expired) | Genzyme |
Plerixafor's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Plerixafor:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
